How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Relugolix–estradiol–norethisterone for treating symptoms of endometriosis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about relugolix CT

Anticipated marketing authorisation indication

2.1

Relugolix–estradiol–norethisterone (relugolix CT) (Ryeqo, Gideon Richter) does not yet have a marketing authorisation in Great Britain. It received a marketing authorisation from the European Commission for the 'symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis'.

Dosage in the marketing authorisation

2.2

The dosage schedule will be available in the summary of product characteristics for relugolix CT.

Price

2.3

The list price for relugolix CT is £72 per pack of 28 tablets (excluding VAT; BNF online, accessed March 2024).